JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

Search

Sanofi

Uždarymo kaina

47.76 -0.54

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

47.39

Max

48.03

Pagrindiniai rodikliai

By Trading Economics

Pajamos

1.4B

1.9B

Pardavimai

3B

11B

P/E

Sektoriaus vid.

16.887

40.048

Pelnas, tenkantis vienai akcijai

1.022

Pelno marža

17.65

Darbuotojai

82,878

EBITDA

2.2B

2.8B

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+30.91% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-16B

122B

Ankstesnė atidarymo kaina

48.3

Ankstesnė uždarymo kaina

47.76

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Sanofi Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-31 06:00; UTC

Uždarbis

Sanofi Upbeat on Sales Outlook After Faster-Than-Expected Growth

2025-07-22 12:03; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi to Buy Vaccine Developer Vicebio for Up to $1.6 Billion -- Update

2025-07-22 05:56; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi to Buy Vaccine Developer Vicebio for Up to $1.6 Billion

2025-08-01 13:16; UTC

Uždarbis

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

2025-08-01 12:40; UTC

Uždarbis

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

2025-07-31 08:15; UTC

Rinkos pokalbiai
Uždarbis

Sanofi's Higher Costs Take Shine off Outlook Raise -- Market Talk

2025-07-31 05:56; UTC

Rinkos pokalbiai
Uždarbis

Sanofi in the Dark on Pharma Tariffs After U.S.-EU Deal -- Market Talk

2025-07-31 05:30; UTC

Uždarbis

Sanofi 2Q Vaccine Sales Increased 10% to EUR1.2B

2025-07-31 05:30; UTC

Uždarbis

Sanofi Says Pharma Launches Sales Increased by 40% in 2Q

2025-07-31 05:30; UTC

Uždarbis

Sanofi 2Q Dupixent Sales Grew 21% to EUR3.8B

2025-07-31 05:30; UTC

Uždarbis

Sanofi Intends to Complete EUR5B Buyback in 2025, With 80% Repurchased to Date

2025-07-31 05:30; UTC

Uždarbis

Sanofi: 2025 Business EPS Guidance Now Includes Expenses From Acquisitions

2025-07-31 05:30; UTC

Uždarbis

Sanofi 2Q Business Operating Profit EUR2.46B

2025-07-31 05:30; UTC

Uždarbis

Sanofi 2Q Adj EPS EUR1.59

2025-07-31 05:30; UTC

Uždarbis

Analysts Saw Sanofi 2Q Business Operating Profit at EUR2.57B

2025-07-31 05:30; UTC

Uždarbis

Analysts Saw Sanofi 2Q Net Sales at EUR9.77B

2025-07-31 05:30; UTC

Uždarbis

Sanofi 2Q Net Pft EUR3.94B

2025-07-31 05:30; UTC

Uždarbis

Analysts Saw Sanofi 2Q Business EPS at EUR1.64

2025-07-31 05:30; UTC

Uždarbis

Sanofi Now Expects 2025 Sales Growth at Constant Currency at High Single-Digit Percentage

2025-07-31 05:30; UTC

Uždarbis

Sanofi Had Seen 2025 Sales Growth at Constant Currency at Mid-To-High Single-digit

2025-07-31 05:30; UTC

Uždarbis

Sanofi 2Q Sales EUR9.99B

2025-07-31 05:30; UTC

Uždarbis

Sanofi Backs 2025 EPS Adj View

2025-07-31 05:30; UTC

Uždarbis

Sanofi Narrows 2025 Sales View

2025-07-31 05:30; UTC

Uždarbis

Sanofi Confirms Expectations of Business EPS Rebound in 2025 Before Buybacks

2025-07-22 08:45; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Sanofi's Vicebio Acquisition Could Make Up for Pipeline Setbacks -- Market Talk

2025-07-22 05:33; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: Deal Won't Have Significant Impact on Guidance for 2025

2025-07-22 05:33; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: Transaction Is Expected to Close in 4Q

2025-07-22 05:33; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi to Buy All of Vicebio for Upfront Payment of $1.15B, Milestone Payments of Up to $450M

2025-07-22 05:32; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: Vicebio Is Privately Held Biotechnology Company Based in London

2025-07-22 05:31; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: Acquisition of Vicebio Seeks to Expand Respiratory Vaccines Pipeline

Akcijų palyginimas

Kainos pokytis

Sanofi Prognozė

Kainos tikslas

By TipRanks

30.91% į viršų

12 mėnesių prognozė

Vidutinis 61.2 USD  30.91%

Aukščiausias 67 USD

Žemiausias 56 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sanofi kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

5 ratings

2

Pirkti

3

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

51.665 / 52.38Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Weak Bullish Evidence

Ilgalaikis periodas

Bullish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.